Clopidogrel intravenous - Ligand Pharmaceuticals

Drug Profile

Clopidogrel intravenous - Ligand Pharmaceuticals

Alternative Names: Captisol-Enabled® clopidogrel; Clopidogrel intravenous - CyDex; MDCO-157; PM 103; sulfobutylether β-cyclodextrin-enabled clopidogrel

Latest Information Update: 30 Mar 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator CyDex Pharmaceuticals; Prism Pharmaceuticals
  • Developer Ligand Pharmaceuticals
  • Class 2 ring heterocyclic compounds; Antiplatelets; Chlorobenzenes; Esters; Pyridines; Small molecules; Thienopyridines
  • Mechanism of Action Platelet ADP receptor antagonists; Platelet aggregation inhibitors; Purinergic P2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Coronary thrombosis

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 30 Jun 2013 The Medicines Company and Ligand Pharmaceuticals terminate their licensing agreement for intravenous clopidogrel
  • 31 Jan 2013 The Medicines Company completes a phase I trial in healthy volunteers in France (NCT01860105)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top